Skip to content

Study · In vitro (cells) · 2005

5 results

Effect of humanin on decreased ATP levels of human lymphocytes harboring A3243G mutant mitochondrial DNA.

Kariya S, Hirano M, Furiya Y, Ueno S

Neuropeptides1 Apr 2005Cited by 31 (Europe PMC)

PMID15752543 (opens in a new tab)DOI10.1016/j.npep.2004.11.004 (opens in a new tab)PepBankPUB-15752543
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In human lymphocytes, muscular TE671 cells and neural SKN-MC cells, humanin increased ATP levels.

    In plain wordsIn human cells grown in the lab, humanin raised the cells' energy molecule ATP.

    Peptide
    Humanin
    Outcome
    IncreaseATP level in lymphocytes, TE671 cells and SKN-MC cells
    Study

    humann: not reported in source

    human lymphocytes, muscular TE671 cells, neural SKN-MC cells
    Outcome group
    Mitochondrial function · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HN increases ATP levels in human lymphocytes, muscular TE671 cells, and neural SKN-MC cells
  2. 02LabIn vitro (cells)Efficacy outcome

    In human lymphocytes, TE671 cells and SKN-MC cells, humanin protected cells from serum deprivation-induced apoptosis.

    In plain wordsIn human cells grown in the lab, humanin protected cells from dying when deprived of serum.

    Peptide
    Humanin
    Outcome
    DecreaseProtection from serum deprivation-induced apoptosis
    Study

    humann: not reported in source

    human lymphocytes, TE671 cells, SKN-MC cells
    Outcome group
    Neuroprotection · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    protects these cells from serum deprivation-induced apoptosis.
  3. 03LabIn vitro (cells)Efficacy outcome

    In serum-supplemented, non-apoptotic cells, humanin also increased ATP levels.

    In plain wordsIn lab cells that were not dying, humanin also raised ATP levels.

    Peptide
    Humanin
    Outcome
    IncreaseATP level in serum-supplemented (non-apoptotic) cells
    Study

    n: not reported in source

    serum-supplemented cells
    Outcome group
    Mitochondrial function · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HN also increased ATP levels of serum-supplemented cells (non-apoptotic cells)
  4. 04LabIn vitro (cells)Efficacy outcome

    In lymphocytes from patients with MELAS and A3243G mutant mtDNA, humanin treatment increased ATP levels.

    In plain wordsIn lab cells carrying the MELAS mitochondrial mutation, humanin raised ATP levels.

    Peptide
    Humanin
    Outcome
    IncreaseATP level in MELAS lymphocytes with A3243G mutant mtDNA
    Study

    humann: not reported in source

    lymphocytes from MELAS patients
    Outcome group
    Mitochondrial function · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    By treatment with HN, the ATP levels of lymphocytes from patients with mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) associated with A3243G mutant mtDNA were increased as well
  5. 05LabIn vitro (cells)Mechanism

    In cells, humanin suppressed mtDNA replication rather than increasing it, so the ATP increase may not result from mitochondrial proliferation.

    In plain wordsIn lab cells, humanin lowered copying of mitochondrial DNA, so the ATP rise was probably not from more mitochondria.

    Peptide
    Humanin
    Outcome
    DecreasemtDNA replication
    Study

    n: not reported in source

    cells, quantitative PCR
    Outcome group
    Mitochondrial function · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HN rather suppressed mtDNA replication.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.